News from halozyme therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-NMS:VPHM,NASDAQ-NMS:HALO)

Feb 01, 2016, 16:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme To Host Fourth Quarter And 2015 Year-End Financial Results Conference Call

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the fourth quarter and full year 2015 on...

Jan 26, 2016, 16:05 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has closed the previously announced $150 million royalty-backed debt transaction...

Jan 21, 2016, 08:35 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE™ Technology

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety...

Jan 11, 2016, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Provides Key Program Updates, 2016 Financial Guidance At 34th Annual JP Morgan Healthcare Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today provided key...

Jan 05, 2016, 16:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics To Present At The 34th Annual J.P. Morgan Healthcare Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on...

Jan 04, 2016, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Enters Into Agreement For $150 Million Non-Dilutive Royalty-Backed Debt Financing

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has entered into a $150 million credit agreement, secured by future...

Dec 21, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) to...

Dec 09, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics and Eisai to present data evaluating the antitumor effects of PEGPH20 in combination with eribulin mesylate in preclinical breast cancer models

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Eisai Inc. will present a scientific poster entitled, "Pegylated Recombinant Human...

Nov 24, 2015, 16:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics To Present At Upcoming Healthcare Conferences

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 2 at...

Nov 17, 2015, 17:00 ET
Halozyme Therapeutics, Inc. Logo

Halozyme To Expand With A Satellite Office In San Francisco

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it will...

Nov 09, 2015, 16:05 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Reports Third Quarter 2015 Financial Results

  Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today...

Nov 05, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

First Patient Dosed in Clinical Trial of Halozyme Investigational Drug PEGPH20 in Combination With Merck Immuno-oncology Drug KEYTRUDA

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the first patient has received its investigational new drug, PEGPH20 in combination...

Nov 04, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Announces First Clinical Dosing Of Janssen's Daratumumab Using ENHANZE™ Technology

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial...

Nov 03, 2015, 16:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday,...

Oct 29, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Announces First Clinical Dosing Of Pfizer's Rivipansel Using Enhanze™ Technology

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the first healthy subject has been dosed in a Phase 1 clinical trial...

Oct 19, 2015, 18:50 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme To Host Third Quarter 2015 Financial Results Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2015 on Monday, November 9 at...

Aug 24, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Appoints Michael J. Labarre As Chief Scientific Officer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today named Michael...

Aug 10, 2015, 16:05 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Reports Second Quarter 2015 Financial Results

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today reported...

Aug 06, 2015, 12:15 ET
Halozyme Therapeutics, Inc. Logo.

UCSF To Study Halozyme PEGPH20 In Pancreatic Cancer Patients Who Are Candidates For Potentially Curative Surgery

 Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced the Pancreas Center at the University of California, San Francisco (UCSF) has...

Aug 05, 2015, 16:31 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Appoints Jeffrey W. Henderson To Board

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced the...